Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer.
Bouchahda M, Boige V, Smith D, Karaboué A, Ducreux M, Hebbar M, Lepère C, Focan C, Guimbaud R, Innominato P, Awad S, Carvalho C, Tumolo S, Truant S, De Baere T, Castaing D, Rougier P, Morère JF, Taieb J, Adam R, Lévi F; ARTBC International. Bouchahda M, et al. Among authors: focan c. Eur J Cancer. 2016 Nov;68:163-172. doi: 10.1016/j.ejca.2016.09.011. Epub 2016 Oct 18. Eur J Cancer. 2016. PMID: 27768923
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
Lévi F, Karaboué A, Saffroy R, Desterke C, Boige V, Smith D, Hebbar M, Innominato P, Taieb J, Carvalho C, Guimbaud R, Focan C, Bouchahda M, Adam R, Ducreux M, Milano G, Lemoine A. Lévi F, et al. Among authors: focan c. Br J Cancer. 2017 Sep 26;117(7):965-973. doi: 10.1038/bjc.2017.278. Epub 2017 Aug 17. Br J Cancer. 2017. PMID: 28817838 Free PMC article. Clinical Trial.
Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial.
Innominato PF, Ballesta A, Huang Q, Focan C, Chollet P, Karaboué A, Giacchetti S, Bouchahda M, Adam R, Garufi C, Lévi FA. Innominato PF, et al. Among authors: focan c. Cancer Med. 2020 Jun;9(12):4148-4159. doi: 10.1002/cam4.3056. Epub 2020 Apr 22. Cancer Med. 2020. PMID: 32319740 Free PMC article. Clinical Trial.
Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer.
Innominato PF, Giacchetti S, Moreau T, Bjarnason GA, Smaaland R, Focan C, Garufi C, Iacobelli S, Tampellini M, Tumolo S, Carvalho C, Karaboué A, Poncet A, Spiegel D, Lévi F; International Association for Research on Time in Biology and Chronotherapy (ARTBC) Chronotherapy Group. Innominato PF, et al. Among authors: focan c. Cancer. 2013 Jul 15;119(14):2564-73. doi: 10.1002/cncr.28072. Epub 2013 Apr 30. Cancer. 2013. PMID: 23633399 Free article.
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
Lévi FA, Boige V, Hebbar M, Smith D, Lepère C, Focan C, Karaboué A, Guimbaud R, Carvalho C, Tumolo S, Innominato P, Ajavon Y, Truant S, Castaing D, De Baere T, Kunstlinger F, Bouchahda M, Afshar M, Rougier P, Adam R, Ducreux M; Association Internationale pour Recherche sur Temps Biologique et Chronothérapie (ARTBC International). Lévi FA, et al. Among authors: focan c. Ann Oncol. 2016 Feb;27(2):267-74. doi: 10.1093/annonc/mdv548. Epub 2015 Nov 16. Ann Oncol. 2016. PMID: 26578731 Free article. Clinical Trial.
Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial.
Innominato PF, Karaboué A, Focan C, Chollet P, Giacchetti S, Bouchahda M, Ulusakarya A, Torsello A, Adam R, Lévi FA, Garufi C. Innominato PF, et al. Among authors: focan c. Int J Cancer. 2021 May 15;148(10):2512-2521. doi: 10.1002/ijc.33422. Epub 2020 Dec 10. Int J Cancer. 2021. PMID: 33270911 Free PMC article.
Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.
Lévi F, Focan C, Karaboué A, de la Valette V, Focan-Henrard D, Baron B, Kreutz F, Giacchetti S. Lévi F, et al. Among authors: focan henrard d, focan c. Adv Drug Deliv Rev. 2007 Aug 31;59(9-10):1015-35. doi: 10.1016/j.addr.2006.11.001. Epub 2007 Jul 4. Adv Drug Deliv Rev. 2007. PMID: 17692427 Review.
Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963).
Innominato PF, Giacchetti S, Moreau T, Smaaland R, Focan C, Bjarnason GA, Garufi C, Iacobelli S, Tampellini M, Tumolo S, Carvalho C, Karaboué A, Lévi F; ARTBC International Chronotherapy Group. Innominato PF, et al. Among authors: focan c. Chronobiol Int. 2011 Aug;28(7):586-600. doi: 10.3109/07420528.2011.597532. Chronobiol Int. 2011. PMID: 21859417 Free article. Clinical Trial.
192 results